Cleared Traditional

K200697 - AtriCure cryoICE cryo-ablation probe (Cryo2), AAtriCure cryoICE cryoSPHERE cryoablation probe (CryoS, CryoS-L)
(FDA 510(k) Clearance)

Dec 2020
Decision
281d
Days
Class 2
Risk

K200697 is an FDA 510(k) clearance for the AtriCure cryoICE cryo-ablation probe (Cryo2), AAtriCure cryoICE cryoSPHERE cryoablation probe (CryoS, CryoS-L). This device is classified as a Device, Surgical, Cryogenic (Class II - Special Controls, product code GXH).

Submitted by AtriCure, Inc. (West Chester, US). The FDA issued a Cleared decision on December 23, 2020, 281 days after receiving the submission on March 17, 2020.

This device falls under the Neurology FDA review panel. Regulated under 21 CFR 882.4250.

Submission Details

510(k) Number K200697 FDA.gov
FDA Decision Cleared Substantially Equivalent - Traditional 510(k) (SESE)
Date Received March 17, 2020
Decision Date December 23, 2020
Days to Decision 281 days
Submission Type Traditional
Review Panel Neurology (NE)
Summary Summary PDF

Device Classification

Product Code GXH — Device, Surgical, Cryogenic
Device Class Class II - Special Controls
CFR Regulation 21 CFR 882.4250

Similar Devices — GXH Device, Surgical, Cryogenic

All 22
cryoICE cryoXT cryoablation probe (cryoXT)
K250371 · AtriCure, Inc. · Apr 2025
iovera? System
K243677 · Pacira Biosciences, Inc. · Dec 2024
AtriCure cryoICE BOX (ACM)
K243157 · AtriCure, Inc. · Oct 2024
cryoICE cryoSPHERE+ Cryoablation Probe (CRYOSP); cryoICE cryoSPHERE+ Cryoablation Probe (CRYOSP-L); cryoICE cryoSPHERE MAX Cryoablation Probe (CRYOSMAX); cryoICE cryoSPHERE MAX Cryoablation Probe (CRYOSMAX-L)
K233170 · AtriCure, Inc. · Oct 2023
iovera System
K220656 · Pacira Biosciences, Inc. · May 2022
Iovera System
K211334 · Pacira Pharmaceuticals, Inc. · Sep 2021